Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals

Basic and Clinical Pharmacology and Toxicology

Volumn 115, Issue 6, 2014, Pages 552-559

  Areberg, Johan ^a   Petersen, Kamilla B ^a   Chen, Grace ^b   Naik, Himanshu ^b  

^a H LUNDBECK A S   (Denmark)

^b Takeda Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; VORTIOXETINE; PIPERAZINE DERIVATIVE; SULFIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MULTIPLE DRUG DOSE; ORAL CLEARANCE; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; AGE; AGED; BLOOD; GENETICS; META ANALYSIS; MIDDLE AGED;

ADULT; AGE FACTORS; AGED; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SULFIDES;

EID: 84911888480     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12256     Document Type: Article

References (17)

1. World Health Organization. Mental health: depression. http://www.who.int/mediacentre/factsheets/fs369/en/. (last accessed on 21 January 2014).
2. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG et al. Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel compound for the treatment of mood and anxiety disorders. J Med Chem 2011;54:3206-21.
3. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
4. Areberg J, Søgaard B, Højer A-M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012;111:198-205.
5. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40:1357-65.
6. Chen G, Lee R, Højer A-M, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013;33:727-36.
7. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry - bioanalytical method validation. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf. 2001 (last accessed on 21 January 2014).
8. Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004;50:1623-33.
9. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Springer Science + Business Media Inc., New York, 2006.
10. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006;23:2036-49.
11. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007;82:17-20.
12. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009;11:558-69.
13. Touchette MA, Slaughter RL. The effect of renal failure on hepatic clearance. DICP 1991;25:1214-24.
14. Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83:898-903.
15. Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharmacol 2012;52:10S-22S.
16. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug application. Clin Pharmacol Ther 2009;85:305-11.
17. Brintellex SmPC. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf. 2014 (last accessed on 21 January 2014).